Related Experiment Video
Updated: Jun 10, 2025

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay
Published on: October 18, 2016
Propionate Decreases Microglial Activation but Impairs Phagocytic Capacity in Response to Aggregated Fibrillar
Andrew Gold1, Sarah Kaye2, Jie Gao2
1Human Nutrition Program and James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
Abstract:
Microglia, the innate immune cell of the brain, are a principal player in Alzheimer's disease (AD) pathogenesis. Their surveillance of the brain leads to interaction with the protein aggregates that drive AD pathogenesis, most notably Amyloid Beta (Aβ). Microglia attempt to clear and degrade Aβ using phagocytic machinery, spurring damaging neuroinflammation in the process. Thus, modulation of the microglial response to Aβ is crucial in mitigating AD pathophysiology. SCFAs, microbial byproducts of dietary fiber fermentation, are blood-brain barrier permeable molecules that have recently been shown to modulate microglial function. It is unclear whether propionate, one representative SCFA, has beneficial or detrimental effects on microglia in AD. Thus, we investigated its impact on microglial Aβ response in vitro. Using a multiomics approach, we characterized the transcriptomic, metabolomic, and lipidomic responses of immortalized murine microglia following 1 h of Aβ stimulation, as well as characterizing Aβ phagocytosis and secretion of reactive nitrogen species. Propionate blunted the early inflammatory response driven by Aβ, downregulating the expression of many Aβ-stimulated immune genes, including those regulating inflammation, the immune complement system, and chemotaxis. Further, it reduced the expression of Apoe and inflammation-promoting Aβ-binding scavenger receptors such as Cd36 and Msr1 in favor of inflammation-dampening Lpl, although this led to impaired phagocytosis. Finally, propionate shifted microglial metabolism, altering phospholipid composition and diverting arginine metabolism, resulting in decreased nitric oxide production. Altogether, our data demonstrate a modulatory role of propionate on microglia that may dampen immune activation in response to Aβ, although at the expense of phagocytic capacity.
Insights
Propionate, a microbial byproduct, dampens microglial immune responses to amyloid beta in Alzheimer's disease models. However, this beneficial effect on inflammation comes at the cost of reduced microglial phagocytosis, impacting disease pathology.
Area of Science:
- Neuroimmunology
- Microbial metabolites
- Alzheimer's disease pathogenesis
Background:
- Microglia, the brain's immune cells, play a key role in Alzheimer's disease (AD) by interacting with amyloid beta (Aβ) aggregates.
- Microglial clearance of Aβ can trigger neuroinflammation, making microglial response modulation critical for AD treatment.
- Short-chain fatty acids (SCFAs) are microbial metabolites that can cross the blood-brain barrier and influence microglial function.
Purpose of the Study:
- To investigate the impact of propionate, a representative SCFA, on microglial responses to Aβ in an in vitro model of Alzheimer's disease.
Main Methods:
- Utilized a multiomics approach (transcriptomics, metabolomics, lipidomics) to analyze immortalized murine microglia.
- Stimulated microglia with Aβ and assessed Aβ phagocytosis and reactive nitrogen species secretion.
- Characterized changes in gene expression, metabolite profiles, and lipid composition.
Main Results:
- Propionate significantly blunted the early inflammatory response of microglia to Aβ, downregulating immune and complement system genes.
- Reduced expression of Aβ-binding scavenger receptors (e.g., CD36, Msr1) and Apoe, while upregulating inflammation-dampening Lpl.
- Altered microglial metabolism, affecting phospholipid composition and arginine metabolism, leading to decreased nitric oxide production and impaired phagocytosis.
Conclusions:
- Propionate modulates microglial immune activation in response to Aβ, potentially offering a therapeutic avenue for AD.
- The anti-inflammatory effects of propionate may be counterbalanced by impaired microglial phagocytic capacity.
- Further research is needed to fully elucidate the complex role of propionate in AD pathophysiology.

